Two hundred twenty-eight members of the House of Representatives yesterday urged the Centers for Medicare & Medicaid Services to abandon its proposal to reduce Medicare Part B payment for drugs acquired through the 340B Drug Pricing Program. “Given the important role that the 340B program plays in our communities, we strongly urge CMS to abandon this proposal and redirect its efforts toward actions to address the cost of drugs via other policies that would not harm our constituents,” the representatives wrote. CMS has proposed to pay for separately payable, non pass-through drugs purchased through the 340B program at the average sales price minus 22.5%, rather than the current rate of ASP plus 6%. Reps. David McKinley (R-WV), Mike Thompson (D-CA) and David Kustoff (R-TN) spearheaded the letter. “The AHA thanks Representatives McKinley, Thompson, and Kustoff for leading this bipartisan effort to protect patient care by urging CMS to rescind its misguided proposal to reduce Medicare Part B payments for 340B hospitals,” said AHA Executive Vice President Tom Nickels.

Related News Articles

Perspective
Public
More than 34.1 million Americans were enrolled in a Medicare Advantage plan in 2025, accounting for 54% of all Medicare beneficiaries. We have seen enrollment…
Headline
The Department of Health and Human Services Feb. 5 in a court filing said it would scrap its current 340B Rebate Model Pilot Program and potentially restart…
Headline
The Coalition to Strengthen America’s Healthcare Feb. 5 released a new research brief examining the impact of proposed site-neutral payment policies on…
Headline
A new AHA blog published Feb. 3 discusses how the 340B Drug Pricing Program serves as an effective solution to some of the nation’s most persistent and…
Blog
Public
Many Americans may be unaware that the services they rely on every day through their local hospital are supported by a program called the 340B Drug Pricing…
Headline
A KFF analysis released Jan. 28 found that Medicare Advantage insurers made nearly 53 million prior authorization determinations in 2024, an increase…